Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Peter Clark, MA, MD, FRCP: A Payer Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




May
04
Today In Oncology
FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer
Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy
Association of Body Size and Bladder Cancer Risk
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Can PFAS Exposure Raise ALL Risk?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo